LEUNG SANDRA
Known title: DirectorCIK: 0001199294
Associated companies
Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 17, 2026
Bristol Myers Squibb sees mixed trial results and dividend focus. Recent articles note BMY's 4.2% dividend yield and the trade‑off investors face between income and growth. Analysts also point to momentum in the stock rally but question whether new drugs can sustain further upside, especially after mixed Phase 3 results for its pulmonary fibrosis treatment. A shift in the company's portfolio toward newer products is also highlighted, adding context to the current market view.
Transaction History
| BHC | ▲ Buy | Grant | 5,789 | $34K | 9/30/2026 | View on chart |
| BHC | ▲ Buy | Grant | 6,845 | $34K | 6/30/2026 | View on chart |
| BHC | ▲ Buy | Grant | 45,871 | $0 | 5/22/2026 | View on chart |
| BHC | ▲ Buy | Grant | 5,946 | $32K | 3/31/2026 | View on chart |
| BHC | ▲ Buy | Grant | 4,586 | $0 | 12/31/2025 | View on chart |
| BHC | ▲ Buy | Grant | 3,673 | $0 | 9/30/2025 | View on chart |
| BHC | ▲ Buy | Grant | 30,149 | $0 | 7/25/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 5,858 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Other | 404 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,790 | $176K | 3/10/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 5,349 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Other | 933 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,259 | $143K | 3/10/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 5,415 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Other | 923 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,298 | $145K | 3/10/2025 | View on chart |
| BMY | ▲ Buy | Option Exercise | 32,096 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Other | 11,837 | $0 | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 10,363 | $654K | 3/10/2025 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,490 | $134K | 3/10/2024 | View on chart |
| BMY | ▲ Buy | Option Exercise | 5,856 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,475 | $133K | 3/10/2024 | View on chart |
| BMY | ▲ Buy | Option Exercise | 35,139 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 11,695 | $629K | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Other | 12,232 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Other | 1,009 | $0 | 3/10/2024 | View on chart |
| BMY | ▲ Buy | Option Exercise | 5,789 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Other | 912 | $0 | 3/10/2024 | View on chart |
| BMY | ▼ Sell | Other | 9,830 | $479K | 11/21/2023 | View on chart |
| BMY | ▼ Sell | Other | 9,830 | $479K | 11/21/2023 | View on chart |
| BMY | ▼ Sell | Other | 2,287 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 4,375 | $287K | 3/10/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 5,787 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Other | 1,070 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 3,505 | $230K | 3/10/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 5,856 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Other | 961 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 3,485 | $229K | 3/10/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 5,349 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Other | 173 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,823 | $185K | 3/10/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 34,726 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Other | 4,240 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 19,916 | $1.3M | 3/10/2023 | View on chart |
| BMY | ▲ Buy | Option Exercise | 6,272 | $0 | 3/10/2023 | View on chart |
| BMY | ▼ Sell | Open Market | 65,000 | $4.9M | 6/6/2022 | View on chart |
| BMY | ▲ Buy | Option Exercise | 6,270 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 2,746 | $188K | 3/10/2022 | View on chart |
| BMY | ▲ Buy | Option Exercise | 4,737 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Other | 67 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 4,673 | $320K | 3/10/2022 | View on chart |
| BMY | ▲ Buy | Option Exercise | 5,787 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Other | 764 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 3,744 | $256K | 3/10/2022 | View on chart |
| BMY | ▲ Buy | Option Exercise | 5,856 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 3,723 | $255K | 3/10/2022 | View on chart |
| BMY | ▲ Buy | Option Exercise | 37,623 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Other | 14,895 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Tax Withholding | 30,015 | $2.1M | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Other | 1,905 | $0 | 3/10/2022 | View on chart |
| BMY | ▼ Sell | Other | 657 | $0 | 3/10/2022 | View on chart |
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
October 12, 2026
BHC appoints interim CEO and looks to raise FY26 EBITDA guidance
Bausch Health announced that its chairman, Thomas J. Appio, will serve as interim chief executive effective immediately. The company and its parent also said they expect to raise the adjusted EBITDA guidance for fiscal year 2026, not including the recently acquired IPR&D business. A separate notice confirms that the firm will release its third‑quarter 2026 results on October 28. Analysts at Zacks included Bausch Health in a recent coverage roundup, highlighting the stock among other health‑care names.
BHC appoints interim CEO and looks to raise FY26 EBITDA guidance. Bausch Health announced that its chairman, Thomas J. Appio, will serve as interim chief executive effective immediately. The company and its parent also said they expect to raise the adjusted EBITDA guidance for fiscal year 2026, not including the recently acquired IPR&D business. A separate notice confirms that the firm will release its third‑quarter 2026 results on October 28. Analysts at Zacks included Bausch Health in a recent coverage roundup, highlighting the stock among other health‑care names.